Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a studyRichard Furie, Victoria P. Werth, Douglas R. Hough et al.|Lupus Science & Medicine|2022Cited by 37
Biological impact of iberdomide in patients with active systemic lupus erythematosusPeter E. Lipsky, Peter Schäfer, Mark Stern et al.|Annals of the Rheumatic Diseases|2022Cited by 37
OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDYVictoria P. Werth, Nikolay Delev, Joan T. Merrill et al.|Annals of the Rheumatic Diseases|2021Cited by 8
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trialVictoria P. Werth, Nikolay Delev, Joan T. Merrill et al.|Journal of the American Academy of Dermatology|2024Cited by 7
SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosusV. Werth, Douglas R. Hough, Richard Furie et al.|Annals of the Rheumatic Diseases|2017Cited by 6